Blenrep (belantamab mafodotin-blmf) / GSK, Pfizer - LARVOL DELTA

Administration- and adverse event-related costs among patients with multiple myeloma treated with B-cell maturation antigen (BCMA)-targeted agents (ASH 2025) - " A 3-year BIM was developed to evaluate administration and AE-related costs for patients with RRMM and ≥1 prior line of therapy who had received belamaf plus bortezomib and dexamethasone (BVd), belamaf plus pomalidomide and dexamethasone (BPd), cilta-cel, ide-cel, or teclistamab. BVd/BPd had substantially lower administration and AE-related costs vs CAR-T and bispecific therapies, which have high costs mostly due to hospitalizations, premedication, and CRS rates."

Adverse events • Clinical • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

A novel and highly effective truncated BCMA safety switch for adoptive cell therapy (ASH 2025) - "We selected BCMA as a safety switch as i) it is not naturally expressed on immune cells commonly used for adoptive cell therapies including T cells, NK cell, NKT cells, gd T cells, and macrophages, ii) its expression is restricted to plasma cells and a small subset of B cells amongst normal human tissues, and iii) highly effective BCMA-targeting bispecific T-cell engagers, such as teclistamab, elranatamab, and linvoseltamab are readily available in the clinic and used for the treatment of multiple myeloma...To assess the efficacy of the safety switch, CD19 CAR T cells co-expressing either ctBCMA or GPI-BCMA were transduced with GFP and cocultured with a B-cell lymphoma cell line at an effector to target ratio of 1:1 in the absence or presence of teclistamab, elranatamab or belantamab mafodotin or their respective isotype antibody controls...Conclusion In conclusion, our results indicate that either ctBCMA or GPI-BCMA may serve as a novel and highly effective safety..."

Clinical • IO biomarker • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • CD52 • CD55 • GPI • PD-L1

Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study (ASH 2025) - "Novel BCMA-targeted therapies, such as CAR T-cells (cilta-cel from 2nd line, ide-cel from 3rd line) and bispecific T-cell engagers (e.g., teclistamab, elranatamab from 4th line), have become new standards of care...Abbreviations: K=carfilzomib; E=elotuzumab; Pom=pomalidomide; d=dexamethasone; Isa=isatuximab; F=panobinostat; R=lenalidomide; Tec=teclistamab; X=selinexor; Elra=elranatamab; Belamaf=belantamab mafodotin; Ixa=ixazomib... This real-world study of 100 MM patients relapsing after anti-BCMA CAR T-cell treatment shows that 91% were in their 4th or 5th line of therapy. A large majority were triple-class exposed, and 52% were lenalidomide-refractory. In the absence of a clear standard of care, common treatments were identified: elotuzumab- and isatuximab-based regimens in the 3rd line; teclistamab and elotuzumab-based options in the 4th line; and teclistamab, elranatamab, and belantamab mafodotin in the 5th line."

CAR T-Cell Therapy • Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Diabetes • Dyslipidemia • Hematological Malignancies • Hypertension • Metabolic Disorders • Multiple Myeloma • Renal Disease

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment exposure patterns indicated a heavily pretreated, triple-class refractory population: proteasome inhibitors (bortezomib 61%, carfilzomib 47%), IMiDs (lenalidomide 67%, pomalidomide 69%), and anti-CD38 monoclonal antibodies (daratumumab 67%). Additional therapies included CAR T-cell therapy (8%), autologous stem cell transplant (23%), Belantamab mafodotin (8%), Talquetamab (10%), and Teclistamab (8%)...Tocilizumab was used in 21% of patients... In comparison to the MagnetisMM-3 trial, this real-world analysis confirms the manageable immune toxicity profile of ELRA, with similarly low rates of grade ≥3 CRS and ICANS. However, the higher 6-month mortality (22.6%) observed in this cohort may reflect broader patient inclusion, including those with significant comorbidities and prior BCMA-directed therapies. Hematologic and infectious toxicities were substantial, reinforcing the need for enhanced monitoring and supportive care strategies in routine clinical use."

Real-world • Real-world evidence • Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Leukemia • Multiple Myeloma • Nephrology • Neutropenia • Plasma Cell Leukemia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Real-world vs. clinical trial data of belantamab mafodotin's ocular toxicities: A comparative analysis (ASH 2025) - "When comparing the Trinetx data to the DREAMM-2 clinical trial, there is a significant difference in the reported risk of keratopathy for patients. Upon consideration, we hypothesize this discrepancy could be caused by a lack of regular follow-up in the real world and underreporting by real-world patients. We also believe that there is better monitoring of ocular toxicities in a clinical trial, which would lead to prompt drug therapy interruption and swift dose adjustment."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Ophthalmology

Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin (ASH 2025) - P1/2 | "In summary, combination therapy with belantamab mafodotin and elotuzumab has shown an encouraging safety profile and a promising preliminary efficacy including among those with prior failure of BCMA-targeted therapy, as previously reported. 1 Our preliminary data suggest that decreased SLAMF7 density may predicts inferior clinical response among poor responders, likely representing one mechanism of escape while the impact on B-cell and T-cell compartments may contribute to disease response in patients with heavily pretreated RRMM. Funding and Product for this study was provided by GSK ."

Clinical • IO biomarker • Hematological Malignancies • Multiple Myeloma • PD-1 • SDC1 • SLAMF7

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis (ASH 2025) - P3 | " In the len-exposed population, the PFS network comprised 8 RCTs (including DREAMM-8) with comparator regimens: carfilzomib + dexamethasone (Kd), Kd + daratumumab (DKd), isatuximab + carfilzomib + dexamethasone (IsaKd), bortezomib + dexamethasone (Vd), DVd, PVd, and selinexor + Vd (SVd). In the absence of head-to-head randomized controlled trials, these ITC data suggested a high probability that PFS consistently favored BPd vs comparator regimens of interest in len-exposed patients with RRMM, with consistent findings in the IPTW analysis reducing uncertainty in the base-case NMA findings."

Retrospective data • Hematological Malignancies • Multiple Myeloma

Real-world efficacy and safety of mezigdomide-dexamethasone in heavily pre-treatred multiple myeloma patients: An Italian case series (ASH 2025) - P1/2 | "Mezigdomide, a novel oral cereblon E3 ligase modulator (CELMoD), has demonstrated promising efficacy and safety in combination with dexamethasone (Mez-D) for relapsed/refractory MM (RRMM), as documented in the phase I–II trial (NCT03374085)...Prior BCMA-directed therapy included belantamab-mafodotin in monotherapy (40%), belantamab mafodotin and teclistamab (10%), or triple exposure to CAR-T cells, belantamab-mafodotin, and teclistamab (10%). Selinexor was used in 30% of cases...However, the high rate of infectious complications underlines the need for appropriate management to prevent early treatment discontinuation. These findings support the potential role of Mez-D combination in routine clinical practice, though larger prospective trials are warranted to confirm its long-term efficacy and safety, particularly in frail MM populations such as the elderly or those with renal impairment."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Pneumonia • Renal Disease • Respiratory Diseases • Targeted Protein Degradation • Thrombocytopenia • CRBN

Real-world data on anti-BCMA CAR-T in Brazil: A single-center retrospective case series (ASH 2025) - "Background : The treatment landscape for relapsed/refractory Multiple Myeloma (R/R MM) in Brazil is unique, with both BCMA CAR-T (ciltacabtagene autoleucel, cilta-cel) and bispecific antibodies (teclistamab, talquetamab, elranatamab) being available for patients who are triple class exposed, but without the necessity of a specific number of previous lines of therapy (LoTs). Ciltacel is also approved based on lenalidomide refractoriness and previous proteasome inhibitor exposure...Of the other 5 patients, 3 did not fulfill CARTITUDE-1 criteria due to cytopenia (2/3), previous BCMA therapy with teclistamab and belantamab mafodotin (1/3) and non-secretory disease (1/3)...Tocilizumab was commonly used (4/7)... Access to CAR-T therapy for multiple myeloma in Brazil is often marked by extensive delays, resulting in a prolonged and complex treatment journey. Most patients wouldn't have fulfilled inclusion/exclusion criteria for the clinical trials the led to ciltacel..."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Multiple Myeloma

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis (ASH 2025) - "All were refractory to daratumumab, bortezomib, cyclophosphamide, and pomalidomide; four were refractory to lenalidomide and belantamab mafodotin; one patient with t(11; 14) was refractory to venetoclax. Three relapsed after anti-BCMA academic CAR-T (HBI0101). Additional therapies included ixazomib (2), carfilzomib (1), elotuzumab (1), and melphalan (1)... Talquetamab produced deep and durable hematologic responses in heavily pretreated patients with R/R AL amyloidosis. Assessment of organ response potential was limited by irreversible organ dysfunction at baseline and short follow-up. Treatment was feasible, including in end-stage renal disease, and the safety profile was manageable without unexpected toxicities."

Clinical • Amyloidosis • Cardiovascular • Congestive Heart Failure • Dental Disorders • Heart Failure • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Renal Disease • Septic Shock • Thrombocytopenia • Xerostomia

Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma (ASH 2025) - "To recapitulate sBCMA-mediated mechanisms of resistance, we next studied the impact of sBCMA on various anti-BCMA immunotherapies (cilta-cel, in-house BCMA-CAR T, teclistamab, belantamab-mafodotin) using an in vitro firefly luciferase-expressing OPM-2 cell line model. In summary, this data confirms the central role of sBCMA in inducing primary resistance to anti-BCMA immunotherapies in MM. To the best of our knowledge, this is the first report on the feasibility of plasmapheresis as an additional debulking measure to lower sBCMA levels in PB and BM in MM patients with high tumor burden. While chemotherapy may have influenced treatment response in our patient, these findings highlight the importance of personalized sBCMA monitoring and sequential debulking strategies to improve responses in a broader population of MM patients receiving anti-BCMA immunotherapies."

Hematological Malignancies • Multiple Myeloma • IL6

Upregulation of BCMA expression by selinexor (ASH 2025) - "Selinexor, Bortezomib, and Dexamethasone was approved based onthe phase III BOSTON trial for the treatment of patients with multiple myeloma who have received atleast one prior therapy...Additionally, we plan to evaluate the correlation between BCMA upregulation andtherapeutic efficacy in vitro by performing cytotoxicity assays after 5 days of 50 nM Selinexor treatment,utilizing BCMA-targeting CAR-T cells, Teclistamab, and Belantamab Mafodotin.ResultsUtilizing dSTORM we monitored BCMA expression in OPM-2 and AMO1 cells during treatment with 10 nMand 50 nM Selinexor...The significant increase in BCMA receptor density suggests thatSelinexor may enhance target antigen availability on the cell surface, potentially improving the efficacy ofBCMA-directed immunotherapies. These initial results support further exploration of Selinexor as asensitizing agent to enhance the effectiveness of BCMA-directed immunotherapies in MM."

IO biomarker • Hematological Malignancies • Multiple Myeloma • XPO1

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study (ASH 2025) - "While BVRd demonstrated high ORRs across all cohorts, MRD- rates were higher in the 1.9SHORT/1.9 STRETCH cohorts, consistent with ER data correlating belamaf Cavg and deep responses.Across cohorts, ocular events were manageable via dose reductions/schedule extensions. Althoughlower-dose-intensity cohorts trended to lower OEF incidence, ocular events were successfully managedacross all cohorts; the 1.9 SHORT/1.9 STRETCH cohorts achieved high OEF resolution rates while inducinghigh MRD- rates with low discontinuation rates due to OEF. In line with clinical observations, ER analysesindicated the potential for higher doses to optimize responses and longer schedules to optimizetolerability."

Clinical • Combination therapy • P1 data • Hematological Malignancies • Multiple Myeloma • Ophthalmology • Transplantation

Phase II trial of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone in multiple myeloma following BCMA CAR T-cell therapy (ASH 2025) - "Four patients received cilta-cel, five patients receivedinvestigational BCMA CAR T-cell therapies, and two patients received both; all patients responded to eachCAR T administered.The ORR was 9/11 (82%) meeting the statistical threshold for efficacy. Bela-KPd utilizing less frequent dosing of Bela led to a favorable efficacy and safety profile,even among patients with prior BCMA CAR T-cell therapy and carfilzomib and pomalidomiderefractoriness. Bela-KPd is a promising regimen for patients following relapse after BCMA CAR T-celltherapy.Partial funding and study drug were provided by GSK and Amgen (ClinicalTrials.gov identifierNCT05789303)."

CAR T-Cell Therapy • IO biomarker • P2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Ophthalmology • Thrombocytopenia

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change (ASH 2025) - P3 | "Background : In DREAMM-7 (NCT04246047), belantamab mafodotin (belamaf) in combination withbortezomib and dexamethasone (BVd) demonstrated significant improvements in progression-freesurvival (PFS; median follow-up, 28.2 months; hazard ratio [HR], 0.41; 95% CI, 0.31-0.53; P<0.001) andoverall survival (median follow-up, 39.4 months; HR, 0.58; 95% CI, 0.43-0.79; P=0.0002) compared withdaratumumab-Vd (DVd) in patients with relapsed/refractory multiple myeloma (RRMM) who had received≥1 prior line of therapy. In DREAMM-8 (NCT04484623), belamaf, pomalidomide, and dexamethasone(BPd) showed a significant PFS benefit (median follow-up, 21.8 months; HR, 0.52; 95% CI, 0.37-0.73; P<0.001) vs pomalidomide-Vd (PVd) in patients with RRMM who had received ≥1 prior line of therapyincluding lenalidomide... No difference in overall QOL was observed between belamaf-based regimens and theirrespective triplet comparators in DREAMM-7 and DREAMM-8, as measured by the EQ-5D-3L..."

Clinical • Patient reported outcomes • Hematological Malignancies • Multiple Myeloma

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis (ASH 2025) - P3 | "In DREAMM-7 (D7; NCT04246047), belamaf, bortezomib, anddexamethasone (BVd) demonstrated significant PFS and OS benefit vs daratumumab-Vd (DVd) in pts withRRMM with ≥1 prior line of therapy (LOT). In DREAMM-8 (D8; NCT04484623), belamaf, pomalidomide, anddexamethasone (BPd) demonstrated a significant PFS benefit vs PVd in pts with RRMM who received ≥1prior LOT, including lenalidomide... In both D7 and D8, BVd and BPd were associated with extended PFS vs standard-of-care(SOC) regimens DVd and PVd, respectively, in patients with FHR MM. Deeper responses with higher ratesof ≥ CR MRD negativity were also observed vs SOC regimens in both studies. mOS was NR in both trials atthe time of this analysis.Funding: GSK (study numbers: 207503; 207499)."

Hematological Malignancies • Multiple Myeloma

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results (ASH 2025) - P1/2 | "No prior BCMA-targeting therapies were allowed, except for belantamab mafodotin, if it was not the last line of therapybefore enrollment...The median prior lines of therapy were 1.8(range, 1–3) with all patients having previous daratumumab and bortezomib therapy. Cyclophosphamidewas administered in 83.3% of patients and 66.7% had previous pomalidomide therapy...Tocilizumab wasadministered in 2 patients, dexamethasone in 1 patient and supplemental oxygen in 2 patients... In this interim report of a phase I/II prospective study in patients with relapsed ALamyloidosis, elranatamab has demonstrated no new safety signals while showing promising efficacy.Data regarding longevity and predictive biomarkers of response stemming from correlative studies arehighly anticipated. Data will be updated at the time of ASH meeting."

Clinical • IO biomarker • P1/2 data • Amyloidosis • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Nephrology • Respiratory Diseases

Can a patient questionnaire (VRAT) reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone? the ukmra prommise d trial (ASH 2025) - "Belamaf in combination with bortezomib and dexamethasone (BVd) demonstrated superiorprogression-free and overall survival for patients with relapsed or refractory multiple myeloma (RRMM)compared to daratumumab, bortezomib and dexamethasone (DREAMM-7 trial) leading to regulatoryapprovals. The ProMMise D trial aims to investigate a patient-centred approach to delivering Belamafwith bortezomib and dexamethasone with less intensive dosing to improve compliance and replacingocular examinations with a simple questionnaire (VRAT).Funding: GSK provided funding and Belamaf supply. This study was also supported by Myeloma UKthrough the UKMRA-MUK- concept and access research programme. Trial registration number:ISRCTN19869915"

Clinical • Hematological Malignancies • Multiple Myeloma • Ophthalmology

Belantamab mafodotin, nirogacestat, and pomalidomide in patients with relapsed/refractory multiple myeloma (ASH 2025) - P1 | "Median priorlines of therapy was 5; 100% were triple exposed (PI, IMiD, anti-CD38 monoclonal antibody), and 5patients had prior high dose melphalan with autologous stem cell transplant. Two patients had priorBCMA treatment; 1 patient had received a BCMA CAR T and a GPRC5D CAR T, and 1 patient had receiveda BCMA CAR T and a BCMA bispecific antibody.The overall response rate (ORR) was 66% including 3 with partial response (PR) and 3 with very goodpartial response (VGPR)...The rate of ocular AEs wassimilar to prior belantamab mafodotin trials and real-world studies. The significant increase inmembrane bound BCMA after starting nirogacestat indicates a possible therapeutic synergy betweenGSIs and BCMA targeted therapies."

Clinical • IO biomarker • Age-related Macular Degeneration • Infectious Disease • Macular Degeneration • Multiple Myeloma • Neutropenia • Ophthalmology • Renal Disease • Retinal Disorders • Thrombocytopenia

Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments (ASH 2025) - P3 | "We soughtto better understand how these standard exams can help to guide dose modifications and managebelamaf-related ocular events. Patients were randomized 1:1 to belamaf, bortezomib, and dexamethasone (BVd) vsdaratumumab-Vd (DVd) in DREAMM-7 or belamaf, pomalidomide, and dexamethasone (BPd) vs PVd inDREAMM-8. Belamaf-related ocular events can be detected using routine eye-care professionalassessments and can be managed and reversed with appropriate dose modifications and follow-up.These events are commonly self-limiting with dose delays due to the regenerative nature of the cornealepithelium. Dose modifications were driven by the more conservative unilateral vision changes; clinicallymeaningful bilateral vision changes were less frequent and transient with high resolution rates,supporting the dose modification approach in DREAMM-7/8.Drug-linker technology licensed from Seagen Inc; monoclonal antibody produced using POTELLIGENTTechnology licensed from BioWa."

Hematological Malignancies • Multiple Myeloma • Ophthalmology

Comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus belantamab mafodotin (belamaf), bortezomib, and dexamethasone and versus belamaf, pomalidomide, and dexamethasone in patients with relapsed / refractory multiple myeloma (RRMM) previously treated with 1–3 prior lines of therapy using a matching-adjusted indirect comparison (ASH 2025) - P3 | "These MAICs demonstrated superior PFS and response rates with cilta-cel compared with 2 belamaf-containing regimens (BVd and BPd). Results should be interpreted with caution as there were substantialdifferences in the pt populations of CARTITUDE-4 vs DREAMM-7 and DREAMM-8. However, adjusted cilta-cel cohort sizes remained large enough for robust comparisons that showed statistically significantdifferences across efficacy outcomes."

Clinical • Hematological Malignancies • Multiple Myeloma

Integrated modeling analyses for belantamab mafodotin in combination with standard of care in patients with Relapsed/Refractory multiple myeloma (RRMM) from dreamm-6, dreamm-7, and dreamm-8 (ASH 2025) - P1/2, P3 | "Introduction: Belantamab mafodotin was investigated for RRMM in combination with lenalidomide +dexamethasone in Arm A of the phase I/II DREAMM-6 (NCT03544281) study, in combination withbortezomib + dexamethasone (BVd) in Arm B of DREAMM-6 and in the phase III DREAMM-7(NCT04246047) study, and in combination with pomalidomide + dexamethasone (BPd) in the phase IIIDREAMM-8 (NCT04484623) study. This analysis demonstrates that in RRMM, higher C1 belantamab mafodotin exposure isassociated with deeper response (≥VGPR), which is critical for improved long-term, durable clinicaloutcomes such as PFS/OS. While lower C1 exposure is associated with improvements in Gr≥2 OEFs, onlymodest benefits in Gr≥3 oAEs and bilateral BCVA worsening to 20/50 or worse were observed with lowerexposure, and there was a demonstrable tradeoff in efficacy. This was further validated by multivariatemodel predictions."

Clinical • Combination therapy • Hematological Malignancies • Multiple Myeloma • Ophthalmology

Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy (ASH 2025) - P3 | "To estimate QALYs for each treatment, health state utilities were informed by DREAMM-7 EQ-5D-3L data and adjusted for adverse event (AE) disutilities; the proportion of patients with grade ≥3 AEsbased on trial data was used to calculate the disutilities for each alternative therapy. BVd led to more LYs (12.0) and QALYs (9.8) compared with all alternative therapies (carfilzomiband dexamethasone [Kd], 8.1 and 6.6, respectively; daratumumab and Kd [DKd], 10.1 and 8.2; isatuximaband Kd [IsaKd], 10.1 and 8.2; bortezomib and dexamethasone [Vd], 6.0 and 4.9; pomalidomide and Vd,8.1 and 6.6; selinexor and Vd, 7.3 and 5.9; DVd, 8.8 and 7.2). BVd led to substantially more LYs and QALYs compared with alternative treatment regimensfor RRMM, highlighting the potential of BVd to extend survival and enhance clinical and quality-of-lifebenefits for these patients. These insights are critical to support clinical and health policy decision-makingin MM at first relapse, supporting..."

Clinical • HEOR • Hematological Malignancies • Multiple Myeloma

Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Study (ASH 2025) - P1/2 | "Most pts achieved ORR within 1 month & the majority remained progression-free at 18 months.Extended dosing intervals and hematologist-led ocular management via the VRA tool enabledpersonalized treatment. The VRA-guided approach allowed symptom-based dosing, resulting in moreconsistent dosing intervals and minimal impact on vision-related daily activities, without compromisingsafety or efficacy.These findings support the continued evaluation of belamaf in 1st line MM setting & suggest the VRA toolas a feasible model for decentralized ocular AE management and dosing guide in clinical practice."

Adverse events • Clinical • Cataract • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Ophthalmology

Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7 (ASH 2025) - P3 | "In DREAMM-7 (NCT04246047), belamaf with bortezomib and dexamethasone (BVd) significantlyprolonged progression-free survival and overall survival vs daratumumab, bortezomib, anddexamethasone (DVd) in patients with RRMM who received ≥1 prior line of therapy. Despite being common with belamaf, ocular events did not have a meaningful impact onHRQOL. Notably, in patients with bilateral worsening of BCVA to 20/50 or worse, HRQOL was maintained,likely due to the transient nature of ocular events and their management with dose reductions anddelays, which have been shown to improve tolerability while maintaining efficacy. The significant efficacybenefits of belamaf prolonged time to deterioration in disease-specific symptoms and physicalfunctioning, including self-care and walking."

Clinical • HEOR • Hematological Malignancies • Multiple Myeloma